HER2+ Breast Cancer

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses systemic agents available and in development for patients with breast cancer who also have brain metastases.

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the lasting impact that the CLEOPATRA and MARIANNE studies have had on the treatment landscape in HER2-positive breast cancer.

Mark Pegram, MD, sheds light on some of the recent groundbreaking trials in HER2-positive breast cancer and how they have come to shape the current treatment paradigm.

Kimberly L. Blackwell, MD, discusses the latest advances for patients with HER2-positive breast cancer and provides insight on the hurdles that still remain.

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the possibility of administering immunotherapy as treatment for patients with HER2-positive breast cancer.

A novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the available treatments for patients with HER2-positive breast cancer, as well as other agents that are in development.

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discusses standard treatment options for patients with HER2-positive breast cancer.

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses MYL-1401O, a proposed biosimilar for trastuzumab (Herceptin), in patients with HER2-positive metastatic breast cancer.

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses the overall treatment paradigm in the neoadjuvant setting of HER2-positive breast cancer.

Howard A. “Skip” Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, a 2014 Giant of Cancer Care in Drug Development, discusses the biggest remaining challenges in treating patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.

Stephen K. Chia, MD, highlights the key findings from the KRISTINE and NSABP B-41 trials and their implications for the treatment of HER2-positive breast cancer.

Michael F. Press, MD, PhD, discusses a retrospective study comparing the original FDA-approved criteria for HER2 gene amplification in breast cancer with the current ASCO-CAP guidelines, and exactly how the 2 sets of guidelines differ from one another.

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.

The FDA has accepted a new drug application for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab.

Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved.

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses the importance of neoadjuvant treatment for patients with HER2-positive breast cancer.

Francisco J. Esteva, MD, PhD, medical oncologist, New York Langone Medical Center, discusses the importance of having a clinical trial of the trastuzumab (Herceptin) biosimilar MYL-1401O for patients with HER2-positive breast cancer.

The European Medicines Agency has validated the marketing authorization application for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.

Hope S. Rugo, MD, discusses the recent findings with MYL-1401O and the role of biosimilars in patients with HER2-positive breast cancer.